Product Name:(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one

IUPAC Name:(3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one

CAS:1383146-20-0
Molecular Formula:C14H20N2O3
Purity:95%
Catalog Number:CM131538
Molecular Weight:264.33

Packing Unit Available Stock Price($) Quantity
CM131538-100mg in stock ǜũ
CM131538-250mg in stock ƿŵȡ
CM131538-1g in stock ȡȐȐ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1383146-20-0
Molecular Formula:C14H20N2O3
Melting Point:-
Smiles Code:O=C1NCCN(CC2=CC=C(OC)C=C2OC)[C@@H]1C
Density:
Catalog Number:CM131538
Molecular Weight:264.33
Boiling Point:436.1±45.0°C at 760 mmHg
MDL No:MFCD22372628
Storage:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products